TECTONIC THERAPEUTIC, INC. Income (Loss) Attributable to Noncontrolling Interest, before Tax
TECTONIC THERAPEUTIC, INC. (TECX) reported Income (Loss) Attributable to Noncontrolling Interest, before Tax of -$12.53 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-14.
Discontinued › Expense Statement › Operating Expenses
us-gaap:IncomeLossAttributableToNoncontrollingInterest · last filed 2024-03-14
- TECTONIC THERAPEUTIC, INC. income (loss) attributable to noncontrolling interest, before tax for fiscal 2023 was -$12.53M, a 111.84% decline from fiscal 2022.
- TECTONIC THERAPEUTIC, INC. income (loss) attributable to noncontrolling interest, before tax for fiscal 2022 was $105.89M.
| Period end | Income (Loss) Attributable to Noncontrolling Interest, before Tax 12 month |
|---|---|
| 2023-12-31 | -$12.53M 10-K · filed 2024-03-14 |
| 2022-12-31 | $105.89M 10-K · filed 2024-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |